Peptide Comparison

MOTS-c vs SS-31: Mechanism, Evidence & Safety

Both get called "mitochondrial peptides," but that label hides how differently they actually work. One signals the nucleus; the other holds the inner mitochondrial membrane together. Here's how they compare.

Last reviewed October 29, 2026 9 min read By Dave Belmonte, Founder
MOTS-c SS-31 Mitochondrial Health
Back to Expert Insights

Quick Comparison

 MOTS-cSS-31 (elamipretide)
ClassMitochondrial-derived peptide (MDP)Synthetic tetrapeptide (Szeto-Schiller peptide)
OriginEncoded within the mitochondrial genome, overlapping the 12S rRNA geneFully synthetic, not genome-encoded
Primary mechanismNuclear translocation and metabolic gene expression under stressBinds cardiolipin in the inner mitochondrial membrane
Research focusInsulin sensitivity, AMPK activation, exercise-mimetic effectsCristae structure, electron transport efficiency, ROS reduction
Clinical trial historyPreclinical and early research; not run through formal drug trialsFormal clinical trials (Barth syndrome, mitochondrial myopathy, certain heart failure contexts)
Regulatory statusNot FDA-approved; sold as a research chemical; 7-5 advisory vote for compounding (July 2026, nonbinding)FDA accelerated approval as Forzinity (Sept 2025) for Barth syndrome only

What Each Compound Is

MOTS-c is a mitochondrial-derived peptide (MDP), meaning it isn't encoded in the cell's nuclear DNA the way most peptides are. Instead, it's encoded within the mitochondrial genome itself, in a region that overlaps the 12S rRNA gene, an unusual origin that sets it apart from nearly every other peptide studied in the health and longevity space. Most of the research interest in MOTS-c centers on metabolic regulation: its effects on insulin sensitivity, its role in activating AMPK (a cellular energy-sensing pathway), and its behavior as an exercise mimetic, meaning it produces some cellular effects similar to those triggered by physical exercise.

SS-31, also known by its drug name elamipretide, is a synthetic tetrapeptide from the Szeto-Schiller family of peptides, an entirely different class of molecule from MOTS-c despite the shared "mitochondrial peptide" label. It isn't derived from mitochondrial DNA and doesn't work through gene expression at all. It's a small, lab-designed peptide built to physically target cardiolipin, a lipid found specifically in the inner mitochondrial membrane, and its research history includes formal clinical trials for specific rare conditions rather than the preclinical, metabolic-focused research base that defines MOTS-c.

Mechanism: Signaling vs Structural

This is the real dividing line between the two compounds. MOTS-c is best described as a signaling peptide. Under metabolic stress, research has shown it can translocate to the cell nucleus and regulate gene expression related to antioxidant response and metabolic adaptation, meaning it changes what the cell does at the genetic level.

SS-31 works nothing like that. It's best described as a structural, protective peptide that acts locally at the inner mitochondrial membrane rather than sending any signal to the nucleus. By binding cardiolipin, it helps stabilize the folded structure of the inner membrane, known as the cristae, and supports more efficient electron transport chain function. Research suggests this can reduce excess production of reactive oxygen species (ROS), a byproduct of inefficient mitochondrial function.

The short version: MOTS-c is a signaling peptide that influences metabolic gene expression from a distance. SS-31 is a structural peptide that works locally at the membrane itself. One changes what the cell does; the other changes how efficiently the existing machinery runs.

Human and Preclinical Evidence

MOTS-c's research base is largely preclinical and mechanistic, built around its role in metabolic regulation. The foundational 2015 study by Lee and colleagues in Cell Metabolism (PMID: 25738459) reported that MOTS-c improved insulin sensitivity and prevented diet-induced obesity in mice. Studies have examined its effects on insulin sensitivity, its activation of the AMPK pathway, and its exercise-mimetic properties, along with its stress-induced translocation to the nucleus to regulate antioxidant and metabolic gene expression.

SS-31/elamipretide has a different kind of research record. It has been studied in formal clinical trials for specific rare conditions, including Barth syndrome, primary mitochondrial myopathy and certain heart failure contexts. The Barth syndrome program, including the TAZPOWER trial (NCT03098797), led to FDA accelerated approval in September 2025, based on improvement in knee extensor muscle strength, with a confirmatory trial still required. That gives SS-31 a far more formal clinical record than MOTS-c.

Regulatory Status and Safety

MOTS-c is sold as a research chemical and is not FDA-approved. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 7-5 in favor of adding MOTS-c to the 503A bulk substances list, but the vote is nonbinding and MOTS-c is not on that list yet (AJMC coverage). SS-31/elamipretide sits in a different regulatory position: the FDA granted it accelerated approval on September 19, 2025 as Forzinity (Stealth BioTherapeutics), a once-daily subcutaneous injection for Barth syndrome in patients weighing at least 30 kg (FDA announcement). That approval is limited to Barth syndrome. In the peptide community, SS-31 is still mostly encountered as a research chemical, which is not the same product as the approved, quality-controlled drug. Neither compound should be treated as an approved, general-use therapy. See the peptide bloodwork guide for the general safety baseline worth running before starting any peptide protocol.

What They Have in Common, and What's Different

In common: both are studied in the context of mitochondrial health, cellular energy production, and aging-related decline in mitochondrial function, which is a big part of why they're often mentioned together and sometimes confused for working the same way.

Different: MOTS-c's research base sits in metabolic and exercise physiology, built around gene expression and insulin sensitivity, while SS-31's research base sits in cardiac and muscle mitochondrial structure, built around a physical interaction with the inner membrane. The mechanisms don't overlap, and neither does the research focus behind each one.

Bloodwork to Track

There isn't a single standard clinical marker that specifically tracks the effect of either compound, and it's worth being upfront about that rather than pointing to a marker that isn't really a dedicated measure of either one. Given MOTS-c's research focus on metabolic regulation and insulin sensitivity, and SS-31's research focus on cardiac and mitochondrial function, a reasonable baseline is a general comprehensive metabolic panel, with a lipid panel worth considering given the metabolic and cardiac angle both compounds are studied around. See the full peptide bloodwork guide for what a baseline panel typically covers.

Choosing Between Them

These aren't really competing options in the way some peptide comparisons are, since they're studied for different angles on mitochondrial health rather than the same outcome. MOTS-c fits a metabolic and exercise-focused approach, while SS-31 fits a structural, membrane-focused approach with a more formal clinical trial history behind it for specific conditions. BioStackIQ's Rate My Stack can score a stack that includes either or both against BioStackIQ's optimization categories, and Build Protocol can help lay out dosing and timing once a direction is chosen.

Where to buy

Compare prescription compounding and research-grade sources:

Where to buy MOTS-c

Frequently Asked Questions

What's the main difference between MOTS-c and SS-31?

They work through completely different mechanisms despite both being called mitochondrial peptides. MOTS-c is a signaling peptide, encoded in the mitochondrial genome itself, that can translocate to the cell nucleus and influence metabolic gene expression. SS-31 (elamipretide) is a structural peptide that binds directly to cardiolipin in the inner mitochondrial membrane, helping stabilize its folded structure rather than changing gene expression at all.

Is SS-31 the same thing as elamipretide?

Yes. SS-31 and elamipretide refer to the same compound, a synthetic tetrapeptide from the Szeto-Schiller peptide family. Elamipretide is the name used in its formal clinical trials, while SS-31 is the name more commonly used in the research and peptide community.

Is MOTS-c or SS-31 FDA-approved?

MOTS-c is not FDA-approved and is sold as a research chemical, although an FDA advisory committee voted 7-5 in July 2026 in favor of adding it to the 503A compounding list (a nonbinding vote). Since October 28, 2026, a draft HHS policy lets licensed 503A pharmacies compound MOTS-c by prescription for injection, under strict conditions. SS-31 is different: elamipretide received FDA accelerated approval on September 19, 2025 as Forzinity, a once-daily injection for Barth syndrome in patients weighing at least 30 kg. That approval covers only Barth syndrome. Research-chemical SS-31 sold online is not the approved drug.

Can MOTS-c and SS-31 be used together?

Because they act through separate mechanisms, one influencing metabolic gene expression and the other supporting inner mitochondrial membrane structure, they are sometimes discussed together as complementary rather than competing approaches to mitochondrial health. Anyone considering combining compounds should look closely at the research behind each individually rather than assuming the combination has been studied as a pair.

What bloodwork should I track when comparing these compounds?

There is no single standard clinical marker that specifically tracks either compound's effect. Given MOTS-c's research focus on metabolic regulation and insulin sensitivity, and SS-31's research focus on cardiac and muscle mitochondrial function, a reasonable baseline is a comprehensive metabolic panel, with a lipid panel worth considering given the metabolic and cardiac research angle. See the peptide bloodwork guide for the full baseline panel.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. MOTS-c is sold as a research chemical and is not FDA-approved. SS-31/elamipretide is FDA-approved only as Forzinity for Barth syndrome; research-chemical SS-31 is not the approved drug. Always consult a qualified healthcare provider before starting any peptide protocol.